The note is the current scenario (Base). Download PDF renders this page on the server, fonts and colours exact; Print uses the browser.
Model Note · JENBURKT PHARMACEUTICAL L · 29 October 2026Page 1 of 2
Model Note
Prepared by the reader · not a MarketPing document
JENBURKT PHARMACEUTICAL L Discounted cash flow · base FY26
JENBURKT PHARMACEUTICAL L
Value per share, this model₹1,187
CMP, 28 Oct 2026₹875.05
Difference35.7%
Growth the CMP implies1.4%/yr
This note states the assumptions and the arithmetic of one model of JENBURKT PHARMACEUTICAL L, built on its filed FY26 standalone statements. The value is the outcome of the assumptions below and nothing else; it is not a fair value, a target or a recommendation.
Assumptions
Input
This model
Filed reference
Revenue growth, 5 years
11% a year
FY26 11.2% · 5-yr CAGR 9.1%
EBITDA margin
23.6%
FY26 23.6% · 5-yr average 23.5%
Depreciation · capex, % of revenue
1.8% · 8.1%, fading to 1.2× depreciation
FY26 1.8% · 8.1%
Working capital, % of added revenue · tax
17.7% · 25.3%
65 working-capital days · effective 25.3%
Discount rate
11.00%
1-yr beta —
After FY31
5% flat · mid-year discounting
—
Net debt · non-controlling interest · non-operating investments
₹(6) · ₹0 · ₹0 cr
FY26 net debt ₹(6) cr
Shares
0.44 crore
0.44 crore today
Source: SEBI results XBRL as filed with BSE/NSE, exchange prices; the reader's assumptions.
Projected cash flow to the firm
₹ crore
FY26
FY27
FY28
FY29
FY30
FY31
Revenue
169
187
208
231
256
284
growth %
11.2
11.0
11.0
11.0
11.0
11.0
EBITDA
40
44
49
54
60
67
Depreciation
(3)
(3)
(4)
(4)
(5)
(5)
NOPAT
27
31
34
38
42
46
less capex
(14)
(15)
(14)
(12)
(9)
(6)
less working-capital build
—
(3)
(4)
(4)
(4)
(5)
Free cash flow to firm
—
15
20
26
32
40
Present value
15
17
20
23
25
Source: the model; base year as filed.
Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in
Model Note · JENBURKT PHARMACEUTICAL L · 29 October 2026Page 2 of 2
From enterprise to equity
PV of the 5 explicit years
100
PV of the terminal value (81% of EV)
418
Enterprise value
518
less net debt
6
less non-controlling interest
0
add non-operating investments
0
Equity value
524
÷ 0.44 crore shares
₹1,187
Source: the model.
Sensitivity, ₹ per share
WACC ↓ · terminal growth →
4.0%
4.5%
5.0%
5.5%
6.0%
10.0%
1,228
1,322
1,435
1,574
1,747
10.5%
1,129
1,207
1,300
1,411
1,548
11.0%
1,044
1,110
1,187
1,279
1,388
11.5%
971
1,027
1,092
1,168
1,257
12.0%
907
956
1,011
1,075
1,149
Source: the model; n/a where terminal growth reaches the discount rate.
Statement
This note is the reader's own model over publicly filed information: SEBI results XBRL filed with BSE and NSE and exchange price data, assembled by MarketPing software; every assumption above is the reader's. It contains no research recommendation, no price target and no opinion by MarketPing on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Historical per-share figures are on the current share count. Where a figure is unavailable the table shows a dash rather than an estimate. Nothing here constitutes investment advice, an offer or a solicitation.
Every figure is the reader's model over filed numbers · No rating, target or fair value is expressedmarketping.in
